AbbVie, in cooperation with Neurocrine Biosciences, announced that the Phase 3 ELARIS UF-I study (M12-815) of elagolix met its primary endpoint.    Results from the first of two pivotal Phase 3 studies demonstrated at month six that elagolix, in combination with low-dose hormone (add-back) therapy, reduced heavy menstrual bleeding with 68.5 percent (p<0.001) of women with uterine fibroids achieving clinical response compared to placebo (8.7 percent), as measured by the alkaline hemati...